- Home
- SQFT vs BDRX Comparison
SQFT vs BDRX Comparison
Compare SQFT & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SQFT | BDRX |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 1.6M |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SQFT | BDRX |
|---|---|---|
| Price | $1.20 | $0.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 76.7K | ★ 7.1M |
| Earning Date | 11-11-2026 | 09-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,814,708.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.14 | $0.60 |
| 52 Week High | $6.40 | $11.88 |
Technical Indicators
Market Signals| Indicator | SQFT | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 35.79 |
| Support Level | $1.17 | $0.61 |
| Resistance Level | $2.37 | $1.52 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 22.50 | 1.18 |
Price Performance
Historical ComparisonAbout SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.